European Journal of Medicinal Chemistry p. 689 - 697 (2002)
Update date:2022-09-26
Topics:
Sharma, Shalabh
Srivastava, Virendra Kishor
Kumar, Ashok
The new 5-bromo-N-[2′-amino(1″-acetyl-5″substitutedaryl-2″- pyrazolin-3″-yl)-1′,3′,4′-oxadiazol-5′- ylmethyl]anthranilic acids 7a-7e and N-[2′-amino-(1″-acetyl-5″-substiutedaryl-2″- pyrazolin-3″-yl)-1′,3′,4′-thiadiazol-5′- ylmethyl]anthranilic acids 6′a-6′c have been synthesised from 5-bromo-N-(2′-aminosubstituedbenzylideneacetyl-1′,3′, 4′-oxadiazol-5′-ylmethyl)anthranilic acids 6a-6e and N-(2′-aminosubstitutedbenzylideneacetyl-1′,3′,4′- thiadiazol-5′-ylmethyl)anthranilic acids 5′a-5′e, respectively. All these compounds have been screened in vivo for their anti-inflammatory and acute toxicity. Compounds 7b and 6′b were found to be potent member of this series, which showed 50.66 and 47.56%, respectively, inflammation inhibitory activity at a dose of 50 mg kg-1 p.o., while standard drug, phenylbutazone, exhibited 45.52% anti-inflammatory activity at the same dose. However, 5-bromo-N-{2′-amino-[1″-acety1-5″-(para-methoxyphenyl)- 2″-pyrazolin-3″-yl]-1′,3′,4′-oxidiazol- 5′-ylmethyl}anthranilic acid (7b) was found to be the most active and less ulcerogcnic compound than the standard drag mid rest of the compounds of this series. The structures of these compounds have been established by IR, 1H-NMR spectroscopic data and elemental analyses.
View MoreNingbo Distant Chemicals Co.,Ltd
Contact:86-574-27862490,27862438
Address:5F-3,#54 DaShaNi street,Ningbo,CHINA
Yangling Ciyuan biotech Co., Ltd.
Contact:86-15802970736
Address:2-1804, International Park Mansion, No.2, South Fengdeng Road, Lianhu District
Contact:86-310-8067016
Address:East Fuhua Road,Tiexi Chemical Industrial Estate,Hebei,China
Ningxia Soochow Agrochemical Limited Company
Contact:(+86)0512 6320 8190
Address:wujiang
SuZhou Ascepion Pharmaceuticals, Inc.(expird)
Contact:0512-86881668
Address:Building C,68Xingqing Road,Suzhou,China.
Doi:10.1021/ja035631i
(2004)Doi:10.1021/ol020229e
(2003)Doi:10.1021/ma021292m
(2003)Doi:10.1021/ol020202v
(2003)Doi:10.1021/jm0491952
(2005)Doi:10.1515/znb-2002-1104
(2002)